Cronos GroupSTU:7CI -0.99%84 EBIT per Share is €-0.04 as of Mar. 2026. GuruFocus rates STU:7CI with a GF Score™ of 84/100 and a GF Value™ of €3.09 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 810 Drug Manufacturers companies, Cronos Group ranks better than 85.68% on this metric.
Cronos Group's EBIT per Share for the
three
months ended in Mar. 2026 was €-0.00.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was €-0.04.
During the past 3 years, the average EBIT per Share Growth Rate was 42.90% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 33.60% per year.
During the past 10 years, the average EBIT per Share Growth Rate was -17.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Cronos Group's EBIT per Share or its related term are showing as below:
STU:7CI'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -176.1 Med: 12.8 Max: 42.9
Current: 42.9
During the past 12 years, the highest 3-Year average EBIT per Share Growth Rate of Cronos Group was 42.90% per year. The lowest was -176.10% per year. And the median was 12.80% per year.
STU:7CI's 3-Year EBIT Growth Rate is ranked better than 85.68% of 810
companies
in the Drug Manufacturers industry
Industry Median: 7.5
vs STU:7CI: 42.90
Cronos Group's EBIT for the
three
months ended in Mar. 2026 was €-1.3 Mil.
Cronos Group (STU:7CI) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Cronos Group EBIT per Share Related Terms
Cronos Group EBIT per Share Historical Data
* Premium members only.
The historical data trend for Cronos Group's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.04
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cronos Group (STU:7CI) has a EBIT per Share of €-0.04 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Cronos Group and its competitors. According to the industry distribution chart, Cronos Group ranks #116 out of 810 companies in the Drug Manufacturers industry, placing it in the top 14.3%.
Is Cronos Group's EBIT per Share too high?
Cronos Group's current EBIT per Share is €-0.04. Based on the distribution chart, Cronos Group ranks #116 out of 810 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Cronos Group has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Cronos Group's EBIT per Share compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Cronos Group ranks #116 out of 810 companies for EBIT per Share. This places Cronos Group in the top 14% of its industry — outperforming the majority of peers. The industry median EBIT per Share is 7.50. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Drug Manufacturers company?
The median EBIT per Share among Drug Manufacturers companies is 7.50, based on 810 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Cronos Group and its competitors. For the Drug Manufacturers industry, the median EBIT per Share is 7.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cronos Group's current EBIT per Share is €-0.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cronos Group stock overvalued right now?
Based on GuruFocus' analysis, Cronos Group (STU:7CI) is currently considered Modestly Undervalued. The stock's GF Value™ is €3.09, compared to a current price of €2.40 — trading 22.2% below its estimated fair value. The current EBIT per Share is €-0.04. Cronos Group's overall GF Score™ is 84/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Cronos Group (STU:7CI), the current EBIT per Share is €-0.04 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cronos Group (STU:7CI) Overvalued in 2026?
Based on GuruFocus' analysis, Cronos Group stock appears to be undervalued.
The current stock price of €2.40 is trading 22.2% below its estimated GF Value™ of €3.09.
GuruFocus considers Cronos Group to be Modestly Undervalued.
Key valuation signals for STU:7CI:
EBIT per Share: €-0.04
GF Value™: €3.09 vs. price of €2.40 (22.2% below fair value)
No single metric tells the full story. See the STU:7CI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cronos Group Inc is a cannabinoid company committed to building disruptive intellectual property by advancing cannabis research, technology, and product development. With a passion for responsibly elevating the consumer experience, the company is building an iconic brand portfolio. Its diverse international brand portfolio includes Spinach, PEACE NATURALS, LIT, and Lord Jones. The company operates in Canada, Israel, and other countries, with the majority of its revenue generated from Canada.
84GF Score
Get the complete analysis for STU:7CI
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:7CI has been successfully added to your 
